Notably, the IRE1α-XBP1 signaling pathway has also been linked to tumor progression and therapy resistance, in part through the positive regulation of IL-6 in several types of cancer, including hepatocellular carcinoma and melanoma. Here, XBP1 is linked to neoplasm.